Saudi Push For Vaccine Manufacturing Ties

(MENAFN- The Arabian Post) Arabian Post Staff -Dubai

Saudi Arabia has stepped up efforts to localise vaccine and pharmaceutical manufacturing, with Industry and Mineral Resources Minister Bandar Alkhorayef holding high-level talks in Lyon aimed at accelerating biopharmaceutical production within the Kingdom.

During meetings with Thomas Triomphe, Executive Vice President and Head of Vaccines at Sanofi, the minister explored pathways for industrial collaboration that would anchor advanced vaccine manufacturing in Saudi Arabia. The discussions centred on technology transfer, research partnerships and the development of local production lines capable of serving both domestic and regional demand.

The engagement forms part of a broader industrial strategy aligned with Vision 2030, which seeks to diversify the economy beyond hydrocarbons and establish high-value manufacturing sectors. Pharmaceuticals and biotechnology have emerged as priority industries, supported by regulatory reforms, investment incentives and the expansion of industrial clusters.

Officials involved in the Lyon discussions indicated that the focus was not limited to packaging or secondary manufacturing but extended to upstream capabilities, including fill-and-finish operations, quality control laboratories and, over time, active pharmaceutical ingredient production. Vaccine manufacturing, in particular, has gained strategic importance following the global supply disruptions experienced during the COVID-19 pandemic, when many countries faced shortages and export restrictions.

Sanofi, headquartered in Paris with major vaccine operations in Lyon, is one of the world's leading producers of influenza, paediatric and travel vaccines. Triomphe oversees a portfolio that includes established immunisation programmes and next-generation vaccine platforms. Saudi Arabia's outreach to such multinational companies reflects a calculated attempt to integrate into global supply chains rather than build isolated facilities.

See also Heroiks opens Middle East hub in Dubai

Riyadh has already taken steps to strengthen its domestic pharmaceutical base. The Kingdom hosts several local manufacturers and has encouraged joint ventures between Saudi firms and international partners. Regulatory oversight has been streamlined through the Saudi Food and Drug Authority, which has worked to align standards with international benchmarks, a prerequisite for export-oriented production.

Industry analysts note that localisation efforts in the Gulf region have intensified as governments seek greater health security and economic resilience. The pandemic exposed vulnerabilities in globalised supply chains, prompting policymakers to consider domestic capacity not only as an economic asset but as a strategic necessity. Saudi Arabia's large healthcare market, driven by population growth and rising non-communicable diseases, offers scale that can justify investment in sophisticated manufacturing infrastructure.

Alkhorayef's visit to Lyon also underscores a diplomatic dimension to industrial policy. France and Saudi Arabia maintain longstanding economic ties across energy, defence and infrastructure. Expanding cooperation into life sciences reflects a shift toward knowledge-based sectors. French pharmaceutical groups have previously signalled interest in the Gulf, citing growing demand for vaccines and biologics.

While concrete agreements have yet to be publicly detailed, the framework discussed in Lyon is understood to include potential training programmes for Saudi engineers and scientists, collaborative research in emerging vaccine technologies and feasibility assessments for local production facilities. Executives familiar with such partnerships caution that vaccine manufacturing requires substantial capital investment and rigorous regulatory validation, often taking several years before commercial output begins.

Saudi Arabia has been investing heavily in industrial zones and logistics infrastructure to support advanced manufacturing. The National Industrial Development and Logistics Program aims to position the Kingdom as a regional hub connecting Europe, Asia and Africa. Pharmaceuticals fit within this strategy, given their high value-to-weight ratio and reliance on efficient distribution networks.

See also Dubai posts record Dh15.6bn property day

Public health experts have welcomed moves to expand local vaccine capacity, arguing that diversified production reduces reliance on imports and can improve responsiveness to outbreaks. However, they stress that sustainability depends on continuous innovation and integration into global research ecosystems. Merely replicating existing products without investing in research and development could limit long-term competitiveness.

Sanofi's vaccine division has been pursuing mRNA and recombinant technologies alongside traditional platforms. Access to such expertise would be significant for Saudi Arabia, which has signalled ambitions to nurture a domestic biotechnology sector. Universities and research centres within the Kingdom have increased collaboration with international institutions, aiming to cultivate skilled human capital capable of supporting advanced life sciences industries.

Economic planners view pharmaceutical localisation as a means to generate skilled employment, reduce import bills and stimulate ancillary industries, from packaging to cold-chain logistics. According to government data, healthcare spending in Saudi Arabia has been rising steadily, with both public and private investment expanding hospital networks and insurance coverage.

Notice an issue? Arabian Post strives to deliver the most accurate and reliable information to its readers. If you believe you have identified an error or inconsistency in this article, please don't hesitate to contact our editorial team at editor[at]thearabianpost[dot]com. We are committed to promptly addressing any concerns and ensuring the highest level of journalistic integrity.

MENAFN15022026000152002308ID1110743193